Literature DB >> 16484807

The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.

Johannes Brettschneider1, Axel Petzold, Daniel Schottle, Annett Claus, Matthias Riepe, Hayrettin Tumani.   

Abstract

BACKGROUND/AIMS: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfH(SMI35) was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Abeta42), the ratio of amyloid beta fragments Abeta42/Abeta40 (Abeta ratio)].
METHODS: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58).
RESULTS: CSF NfH(SMI35) was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Abeta42 and Abeta ratios in AD were lower than in MCI and controls (p < 0.05 each).
CONCLUSION: The diagnostic potential of NfH(SMI35) is not superior to that of other CSF markers. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16484807     DOI: 10.1159/000091436

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  26 in total

1.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

2.  Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.

Authors:  Shaohui Wang; Lingqiang Zhu; Hairong Shi; Hongyun Zheng; Qing Tian; Qun Wang; Rong Liu; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

Review 3.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

4.  Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ.

Authors:  Parvathi Rudrabhatla; Philip Grant; Howard Jaffe; Michael J Strong; Harish C Pant
Journal:  FASEB J       Date:  2010-07-12       Impact factor: 5.191

5.  CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors:  T J Barber; A Imaz; M Boffito; J Niubó; A Pozniak; R Fortuny; J Alonso; N Davies; S Mandalia; D Podzamczer; B Gazzard
Journal:  J Neurovirol       Date:  2017-12-26       Impact factor: 2.643

Review 6.  Topographic regulation of neuronal intermediate filaments by phosphorylation, role of peptidyl-prolyl isomerase 1: significance in neurodegeneration.

Authors:  B K Binukumar; Varsha Shukla; Niranjana D Amin; Preethi Reddy; Suzanne Skuntz; Philip Grant; Harish C Pant
Journal:  Histochem Cell Biol       Date:  2013-06-23       Impact factor: 4.304

Review 7.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

Review 8.  Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders.

Authors:  Aidong Yuan; Ralph A Nixon
Journal:  Brain Res Bull       Date:  2016-09-05       Impact factor: 4.077

Review 9.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

Review 10.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.